よむ、つかう、まなぶ。
Global Health Vision of Ministry of Health, Labour and Welfare of Japan (15 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_42939.html |
| 出典情報 | 「厚生労働省国際保健ビジョン」の公表について（8／26）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
JIHS will work closely with the MHLW, Pharmaceuticals and Medical Devices Agency
(PMDA), ACPHEED, and other relevant organizations to strengthen the information
collection and analysis system for infectious diseases, develop and secure human
resources for responding to infectious disease crises, and establish a comprehensive
research and development infrastructure from basic research to clinical trials. We will
continue to explore specific measures to enhance all functions required of JIHS.
(4) Building an Indo-Pacific Health Strategy
In order to further strengthen cooperation in the field of health, medical care and
long-term care with Asian and Indo-Pacific countries, Japan should take the lead in
developing an Indo-Pacific health strategy based on cooperation in the Indo-Pacific,
including Asia.
Specifically, the "Ecosystem for the Development of Pharmaceuticals and Medical
Devices" with Asian countries and Indo-Pacific countries, the Cyclical Elderly Health
Strategy, which involves the utilization of foreign human resources in the long-term
care and other fields and support for the international expansion of long-term care
providers, as well as the international expansion of medical care will be promoted.
(4-1) Development of "Ecosystem for Development of Pharmaceuticals and Medical
Devices”
① Purpose
Access to essential medicines and medical devices is an important element of
UHC in the context of the SDGs. Japan needs to contribute to improving health in
other countries, including Asian countries, through enhancing access to medicines
and medical devices in these regions. Under various government initiatives2, efforts
have been made to improve patient’s accessibility to medicines and medical devices
in Asian countries with UHC in mind by harmonizing pharmaceutical regulations and
developing clinical development systems.
Regarding the harmonization of pharmaceutical regulations, the Asia Training
Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC) was
2
Under the "Basic Policy Toward the Asian Health Initiative," the "Asian Grand Design for Regulatory
Harmonization of Pharmaceuticals and Medical Devices" (decided by the Headquarters for Health and Medical
Care Strategy Promotion on June 20, 2019) and the "Implementation Strategy for the Asian Grand Design for
Regulatory Harmonization of Pharmaceuticals and Medical Devices" (decided by the Headquarters for Health
and Medical Care Strategy Promotion on July 14, 2020) have been formulated.
15
(PMDA), ACPHEED, and other relevant organizations to strengthen the information
collection and analysis system for infectious diseases, develop and secure human
resources for responding to infectious disease crises, and establish a comprehensive
research and development infrastructure from basic research to clinical trials. We will
continue to explore specific measures to enhance all functions required of JIHS.
(4) Building an Indo-Pacific Health Strategy
In order to further strengthen cooperation in the field of health, medical care and
long-term care with Asian and Indo-Pacific countries, Japan should take the lead in
developing an Indo-Pacific health strategy based on cooperation in the Indo-Pacific,
including Asia.
Specifically, the "Ecosystem for the Development of Pharmaceuticals and Medical
Devices" with Asian countries and Indo-Pacific countries, the Cyclical Elderly Health
Strategy, which involves the utilization of foreign human resources in the long-term
care and other fields and support for the international expansion of long-term care
providers, as well as the international expansion of medical care will be promoted.
(4-1) Development of "Ecosystem for Development of Pharmaceuticals and Medical
Devices”
① Purpose
Access to essential medicines and medical devices is an important element of
UHC in the context of the SDGs. Japan needs to contribute to improving health in
other countries, including Asian countries, through enhancing access to medicines
and medical devices in these regions. Under various government initiatives2, efforts
have been made to improve patient’s accessibility to medicines and medical devices
in Asian countries with UHC in mind by harmonizing pharmaceutical regulations and
developing clinical development systems.
Regarding the harmonization of pharmaceutical regulations, the Asia Training
Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC) was
2
Under the "Basic Policy Toward the Asian Health Initiative," the "Asian Grand Design for Regulatory
Harmonization of Pharmaceuticals and Medical Devices" (decided by the Headquarters for Health and Medical
Care Strategy Promotion on June 20, 2019) and the "Implementation Strategy for the Asian Grand Design for
Regulatory Harmonization of Pharmaceuticals and Medical Devices" (decided by the Headquarters for Health
and Medical Care Strategy Promotion on July 14, 2020) have been formulated.
15